JUNO THERAPEUTICS INC's ticker is JUNO and the CUSIP is 48205A109. A total of 178 filers reported holding JUNO THERAPEUTICS INC in Q2 2017. The put-call ratio across all filers is 1.38 and the average weighting 1.0%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q1 2017 | $1,997,000 | +17.7% | 90,000 | 0.0% | 0.13% | +20.0% |
Q4 2016 | $1,697,000 | -37.2% | 90,000 | 0.0% | 0.11% | -33.3% |
Q3 2016 | $2,701,000 | -21.9% | 90,000 | 0.0% | 0.16% | -22.2% |
Q2 2016 | $3,460,000 | +0.9% | 90,000 | 0.0% | 0.21% | +10.4% |
Q1 2016 | $3,428,000 | -13.4% | 90,000 | 0.0% | 0.19% | -3.0% |
Q4 2015 | $3,957,000 | – | 90,000 | – | 0.20% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Biomark Capital Management Co. LLC | 2,168,601 | $40,878,000 | 84.62% |
Crestline Management, LP | 17,348,799 | $327,025,000 | 81.61% |
Omega Fund Management, LLC | 1,229,512 | $23,176,000 | 18.81% |
SIB LLC | 100,000 | $1,885,000 | 1.52% |
BB BIOTECH AG | 1,870,000 | $35,250,000 | 1.31% |
Clearline Capital LP | 116,200 | $2,190,000 | 0.99% |
ARK Investment Management | 141,976 | $2,676,000 | 0.97% |
Clarius Group, LLC | 117,896 | $2,222,000 | 0.94% |
SCOPIA CAPITAL MANAGEMENT LP | 1,778,724 | $33,529,000 | 0.64% |
Baillie Gifford | 11,061,955 | $208,518,000 | 0.34% |